echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The fast-growing Chinese pharmaceutical market is becoming the next stop for multinational pharmaceutical companies

    The fast-growing Chinese pharmaceutical market is becoming the next stop for multinational pharmaceutical companies

    • Last Update: 2020-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Xinda Biopharmaceutical announced the appointment of Dr. Liu Yongjun, a world-renowned scientist in the biopharmaceutical industry, as President of the Group.
    joined Xinda Bio, Dr. Liu will be responsible for the Group's global research and development, pipeline strategy, business cooperation and international business.
    understood that Dr. Liu has been deeply involved in the biopharmaceutical industry for more than 30 years and is a world-renowned scientist in the fields of immunology, oncology and translational medicine.
    , Dr. Liu has worked for several large multinational pharmaceutical companies, including Sanofi.
    his tenure, Dr. Liu has significantly enhanced his drug research and development capabilities and comprehensively enriched early innovation pipelines in a number of therapeutic areas, especially in the core biopharmaceutical fields of "tumor" and "immunity".
    has also significantly increased the efficiency of first-In-Class and Best-In-Class drugs during his tenure.
    , in fact, from the background, the rapid development of China's pharmaceutical market, is becoming the next journey of multinational pharmaceutical companies.
    the world is in the golden age of biopharmaceutical development, the power of innovation is rapidly rising.
    years, China's pharmaceutical market has undergone tremendous changes with the acceleration of domestic drug review and approval, as well as the continued promotion of new policies to encourage drug innovation and volume procurement.
    era of multinational pharmaceutical companies lying to win will come to an end, domestic innovative drugs are rising.
    industry has predicted that in the next three to five years, China's innovative pharmaceutical companies will have a global market impact on the "big drugs."
    background, the Chinese market has attracted a large number of multinational pharmaceutical tycoons to return.
    example, in early 2016, Tan Lingshi, former vice president of research and development at Pfizer and general manager of Pfizer's China research and development center, embarked on an entrepreneurial path and became the founder of The Pulse Biopharmaceutical Technology (Shanghai) Co., Ltd.
    , Jiang Ningjun, former global vice president of Sanofi and president of the Asia Pacific Research and Development Center, became CEO of Keystone Pharmaceuticals.
    March 2017, Mei Jianming, executive director of Xinjiyuan's global clinical research and development department, left his "old home" and returned to China to start Deki Pharmaceuticals.
    May 10, 2017, Sean Shan, former general manager of Pfizer Global Innovation Pharmaceuticals China, joined Takeda as head of Greater China and president of China.
    April 23, 2018, Wu Xiaobin, former President of Pfizer Core Healthcare Greater China, joined Baiji Shenzhou as General Manager and President of the Company in China.
    March 1, 2019, Goliath Pharmaceuticals announced the appointment of Dr. Zhengqing Li, former Global Vice President of Merca East and General Manager of China Research and Development Center, as the Company's First Medical Officer and President of Research and Development in Greater China.
    April 2020, Huang Weidong, former President of Bayer CropScience Greater China, joined Yiteng Pharmaceuticals and served as the first operations officer, fully responsible for the commercial operation of Yiteng Pharmaceuticals Group.
    it is not difficult to see that domestic pharmaceutical companies for talent selection is no longer limited to the domestic.
    Wu Xiaobin's expression after joining Baiji Shenzhou may represent the psychological activity of a group of Chinese executives returning home from multinational pharmaceutical companies: "Pfizer is doing very well in the industry.
    whether it's production research and development or commercialization, compliance is very good... But accordingly, the challenge for me personally at this time is relatively small.
    have so many capable colleagues, they also need to let everyone have their own space.
    I need to have another goal that makes me excited.
    ", compared with the complex management level of multinational pharmaceutical companies, in start-ups, the motivation is very different, and decision-making is fast and efficient.
    " industry believes that in recent years, domestic and foreign pharmaceutical executives have been mobilized, but whether it is business adjustment or market reshuffle, talent has always been the core element of success.
    as local pharmaceutical companies enter the transition breakthrough period, the talent competition between them and multinational pharmaceutical companies will become more and more intense.
    how to attract more and more professional talent in the competition, this will become in the sunrise industry enterprises have to pay attention to a lesson.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.